Is Compounded Semaglutide Still Legal? October 2026 Update

Compounded semaglutide is not covered by a blanket shortage exemption in October 2026. Some patient-specific compounding may meet the law's conditions, but routinely selling copies of an available approved drug is restricted. A prescription alone does not establish that every compounded product is lawful.¹

What changed after the shortage

FDA determined that the semaglutide injection shortage was resolved in February 2025. The subsequent enforcement transition ended for 503A compounders following the April 2025 court decision, and for 503B facilities in May 2025. A local pharmacy being temporarily out of a dose does not recreate a national shortage exemption.¹

That is why older articles saying “compounding is allowed because Wegovy is in shortage” need a date and a correction. Our earlier compounding timeline explains the transition; the practical question now is the legal basis for your individual prescription.

503A and 503B are different frameworks

For 503A, a prescriber can determine and document that a change produces a significant difference for a particular patient. For 503B, additional restrictions apply to bulk substances and copies. FDA's April 2026 clarification says semaglutide and tirzepatide were on neither the shortage list nor the 503B bulks list.¹

The April 2026 proposal to exclude these substances from the 503B bulks list is a proposed rulemaking step, not a new FDA approval for compounded drugs.² Do not treat a pending policy document as permission to ignore current requirements.

Adding B12 does not automatically solve the problem

A vitamin addition is not, by itself, proof that a product meets the applicable exception. FDA's September 2026 Empower Pharmacy warning letter described semaglutide/cyanocobalamin and tirzepatide/niacinamide products as apparent copies and questioned repeated, seemingly pre-generated determinations of significant difference.³

The letter is about the named facility and inspected practices. It does not prove that every prescription from every telehealth service is defective. It does show why “customized with vitamins” is an incomplete explanation for consumers.

Ask your prescriber to explain the medical reason in your case. A general marketing sentence about customization is less useful than a clear clinical explanation of why an available approved formulation does not meet your need.

Four checks before the next refill

1. Get the dispensing pharmacy's full legal name and confirm its license with the relevant state board.
2. Ask for the exact active ingredient and formulation. “Semaglutide” in an advertisement is not a complete vial description.
3. Ask your clinician to explain the patient-specific basis for compounding and document the treatment plan.
4. Confirm the dose in milligrams, concentration, syringe measurement, storage, and beyond-use date for this exact fill.

FDA has raised separate concerns about semaglutide salts and dosing errors. Compounded drugs are not FDA-approved, and their safety, effectiveness, and quality are not reviewed in the same way as approved products.⁴ Our dosing-error guide explains why you must not reuse a syringe-unit instruction from a different vial.

What this means for your care

Do not abruptly improvise a substitute if a provider changes its offering. Ask your clinician about an approved option, a lawful individualized prescription if appropriate, and a safe plan for any interruption. Discuss the ongoing expense as well as the first fill.

Our reviews of CoreAge Rx and Ondra Health describe their published offerings; appearing in a review or on the semaglutide board is not a legal opinion about a particular prescription. For an approved pharmacy route, see NovoCare Pharmacy. Use compounded versus brand-name treatment to prepare the questions for your prescriber.